SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPorvair Regulatory News (PRV)

Share Price Information for Porvair (PRV)

Share Price is delayed by 15 minutes
Get Live Data
830.00    14.00 (1.72%)
Bid:
824.00
Ask:
828.00
Spread: 4.00 (0.485%)
Market Cap: £382.60m
PRV Live PriceLast checked at - London Stock Exchange

Intraday Porvair Share Chart

Board Changes

25 Sep 2025 07:00

RNS Number : 6929A
Porvair PLC
25 September 2025
 

 

For immediate release 25 September 2025

 

 

Porvair plc

("Porvair" or the "Group" or the "Company")

 

Board Changes

Lisa Anson

Lisa Anson has been appointed as Non-Executive Director of the Company with effect from 1 October 2025.

Lisa is currently Chief Executive Officer of Redx Pharma limited, a UK based, privately held clinical-stage biotech business; a position she held when Redx was publicly listed on AIM. In addition, she is a Supervisory Board Member for Apoplex Medical Technologies GmBH, a private German company and is an elected Board Member of the UK BioIndustry Association (BIA). She was previously a Board Member and then Chair at the Association of the British Pharmaceutical Industry (ABPI).

Lisa's career spans almost 30 years in the pharmaceutical and Biotech industry including more than twenty years at AstraZeneca Plc. She has extensive global leadership and commercial experience, including several USA based roles and most recently was Country President for the UK and Ireland.

On appointment, Lisa will join the Audit Committee, Remuneration Committee and Nomination Committee of Porvair.

Porvair confirms that there are no further matters in relation to Lisa Anson's appointment to be disclosed pursuant to the requirements of paragraph 6.4.8 of the Listing Rules of the UK Listing Authority.

Sally Martin

Having completed 9 years as a Non-Executive Director at Porvair, Sally Martin will retire from the Board on 4 November 2025.

Sheena Mackay

Following Sally's retirement, Sheena Mackay will be appointed Senior Independent Director of the Board and the Non-Executive Director responsible for employee engagement, in addition to her role as Chair of the Remuneration Committee.

For further information, please contact:

Porvair plc

+44 (0)1553 765 500

Hooman Caman Javvi, Chief Executive Officer

Andrew Douglass, Group Company Secretary

 

Burson Buchanan

+44 (0)207 466 5000

Charles Ryland / Stephanie Whitmore

 

 

Notes to editors

 

Porvair plc

Porvair is a group of specialist filtration, laboratory and environmental technology businesses. Its businesses design and manufacture a range of bespoke consumable filtration products that are used in a range of niche filtration markets. It operates in three divisions: Aerospace & Industrial; Laboratory; and Metal Melt Quality.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEZLFLEKLZBBF
Date   Source Headline
9th Dec 20217:00 amRNSPre-close trading update and Notice of Results
23rd Nov 202112:30 pmRNSHolding(s) in Company
5th Nov 20214:40 pmRNSSecond Price Monitoring Extn
5th Nov 20214:35 pmRNSPrice Monitoring Extension
8th Oct 20214:40 pmRNSSecond Price Monitoring Extn
8th Oct 20214:35 pmRNSPrice Monitoring Extension
27th Sep 20214:41 pmRNSSecond Price Monitoring Extn
27th Sep 20214:35 pmRNSPrice Monitoring Extension
16th Sep 20213:31 pmRNSDirector/PDMR Shareholding
14th Sep 20217:00 amRNSNine Month Trading Update
11th Aug 20214:41 pmRNSSecond Price Monitoring Extn
11th Aug 20214:35 pmRNSPrice Monitoring Extension
10th Aug 20214:40 pmRNSSecond Price Monitoring Extn
10th Aug 20214:35 pmRNSPrice Monitoring Extension
4th Aug 20217:00 amRNSBlock listing Interim Review
5th Jul 20217:00 amRNSHalf Year Results 2021
30th Jun 20217:00 amRNSTotal Voting Rights
29th Jun 20214:41 pmRNSSecond Price Monitoring Extn
29th Jun 20214:36 pmRNSPrice Monitoring Extension
23rd Jun 20214:41 pmRNSSecond Price Monitoring Extn
23rd Jun 20214:35 pmRNSPrice Monitoring Extension
10th May 20214:40 pmRNSSecond Price Monitoring Extn
10th May 20214:36 pmRNSPrice Monitoring Extension
21st Apr 20212:40 pmRNSGrant of LTSP awards
20th Apr 202112:30 pmRNSAGM resolutions and Board changes
20th Apr 20217:00 amRNSAGM Trading Update
1st Apr 20214:28 pmRNSTotal Voting Rights
17th Mar 20214:57 pmRNSHolding(s) in Company
16th Mar 20212:01 pmRNSHolding(s) in Company
2nd Mar 20214:40 pmRNSSecond Price Monitoring Extn
2nd Mar 20214:35 pmRNSPrice Monitoring Extension
1st Mar 20213:27 pmRNSTotal Voting Rights
26th Feb 20217:00 amRNSAcquisition of Kbiosystems Limited
22nd Feb 20213:00 pmRNSHolding(s) in Company
19th Feb 20214:35 pmRNSPrice Monitoring Extension
10th Feb 20214:36 pmRNSPrice Monitoring Extension
8th Feb 20217:00 amRNSBlock listing Interim Review
8th Feb 20217:00 amRNSTotal Voting Rights
3rd Feb 20214:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20214:36 pmRNSPrice Monitoring Extension
3rd Feb 20219:42 amRNSHolding(s) in Company
2nd Feb 20217:00 amRNSGrant of LTSP awards
1st Feb 20217:00 amRNSFinal Results
6th Jan 20214:41 pmRNSSecond Price Monitoring Extn
6th Jan 20214:35 pmRNSPrice Monitoring Extension
30th Dec 20203:30 pmRNSHolding(s) in Company
30th Dec 20203:30 pmRNSHolding(s) in Company
9th Dec 20203:47 pmRNSHolding(s) in Company
8th Dec 20207:00 amRNSPre-close trading update
23rd Nov 20204:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.